Global pharmaceutical giant Boehringer Ingelheim has signed a new five-year ... Brands include Frontline, Jardiance and NexGard. The firm’s revenue last year was approximately $30.1 billion ...

Boehringer Ingelheim has released data on its patient reach, sales, and investments during 2024, and is looking ahead to the company’s anticipated offerings for the rest of 2025. In a press release on ...

Boehringer Ingelheim Korea has marked a turning point ... the company is focusing on parasiticides as a core pipeline, with products like NexGard Spectra and NexGard Combo receiving positive responses ...

Cognizant, as the prime system integrator, began the Boehringer Ingelheim project by codeveloping a program roadmap, agile methodology, and implementation workflow. The overall scope of the ...

Feb 25 (Reuters) - Boehringer Ingelheim has prevailed in the trial of two lawsuits claiming that its discontinued heartburn drug Zantac caused cancer, both of which had previously ended with hung ...

With advancements in veterinary medicine, pet owners now have access to effective solutions, such as Boehringer Ingelheim's NexGard® COMBO for cats. This groundbreaking, easy-to-apply formula provides ...

Hyderabad, Telangana, India: Boehringer Ingelheim India has signed a Memorandum of Understanding (MoU) with Hyderabad-based EMRI Green Health Services a GVK enterprise, the operator of the ...

The product donation of NexGard® PLUS chews includes monthly flea, tick, heartworm disease, roundworm, and hookworm protection from Boehringer Ingelheim. "At Boehringer Ingelheim, we are deeply ...

Boehringer Ingelheim announced it will buy Nerio Therapeutics for $1.3 billion Monday morning. The German drugmaker is bolstering its immuno-oncology pipeline by adding the San Diego-based drug ...

Milestones reached in cardiovascular, renal, metabolic health (CRM), and oncologyFurther data read-outs expected in 2024 in oncology, mental health, and pulmonary fibrosisStrong first half net ...

Milestones reached in cardiovascular, renal, metabolic health (CRM), and oncology Further data read-outs expected in 2024 in oncology, mental health, and pulmonary fibrosis Strong first half net sales ...